NYSEMKT: APUS
Apimeds Pharmaceuticals Us Inc Stock Ownership - Who owns Apimeds Pharmaceuticals Us?

Insider buying vs selling

Have Apimeds Pharmaceuticals Us Inc insiders been buying or selling?

No trades
There has been no insiders buying vs selling in the past 12 months.

Be the first to know when APUS insiders and whales buy or sell their stock.

APUS Shareholders

What type of owners hold Apimeds Pharmaceuticals Us Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Inscobee Inc46.13%5,801,234$7.77MInsider
Erik C. Emerson5.96%750,000$1.01MInsider
Jakap Koo5.12%643,885$862.81kInsider
Christopher Kim2.21%277,500$371.85kInsider
Hemenway Trust Co LLC2.18%274,000$367.16kInstitution
Vanguard Group Inc0.47%58,992$79.05kInstitution
Geode Capital Management LLC0.28%34,888$46.75kInstitution
Jane Street Group LLC0.22%27,188$36.43kInstitution
Ubs Group Ag0.00%582$779.88Institution
Bank Of America Corp0.00%40$53.60Institution

1 of 2

APUS vs Pharmaceutical Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
APUS3.15%59.42%
QNTM3.30%0.00%
BFRI20.07%27.76%
ZSTK0.01%99.99%
CABR1.13%19.50%Net SellingNet Selling

Apimeds Pharmaceuticals Us Stock Ownership FAQ

Who owns Apimeds Pharmaceuticals Us?

Apimeds Pharmaceuticals Us (NYSEMKT: APUS) is owned by 3.15% institutional shareholders, 59.42% Apimeds Pharmaceuticals Us insiders, and 37.43% retail investors. Inscobee Inc is the largest individual Apimeds Pharmaceuticals Us shareholder, owning 5.80M shares representing 46.13% of the company. Inscobee Inc's Apimeds Pharmaceuticals Us shares are currently valued at $7.54M.

If you're new to stock investing, here's how to buy Apimeds Pharmaceuticals Us stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.